Author:
Maekawa Masato,Taniguchi Terumi,Nishio Kazuto,Sakai Kazuko,Matsushita Kazuyuki,Nakatani Kaname,Ishige Takayuki,Ikejiri Makoto,Nishihara Hiroshi,Sunami Kuniko,Yatabe Yasushi,Hatanaka Kanako C.,Hatanaka Yutaka,Yamamoto Yoshihiro,Fukuyama Keita,Oda Shinya,Saito Kayoko,Yokomura Mamoru,Kubo Yuji,Sato Hiroko,Tanaka Yoshinori,Fuchioka Misa,Yamasaki Tadashi,Matsuda Koichiro,Kurachi Kiyotaka,Funai Kazuhiro,Baba Satoshi,Iwaizumi Moriya
Abstract
AbstractTo implement precision oncology, analytical validity as well as clinical validity and utility are important. However, proficiency testing (PT) to assess validity has not yet been systematically performed in Japan. To investigate the quality of next-generation sequencing (NGS) platforms and cancer genome testing prevalent in laboratories, we performed pilot PT using patient samples. We prepared genomic DNA from the cancer tissue and peripheral blood of 5 cancer patients and distributed these to 15 laboratories. Most participating laboratories successfully identified the pathogenic variants, except for two closely located KRAS variants and 25 bp delins in EGFR. Conversely, the EGFR L858R variant was successfully identified, and the allele frequency was similar for all the laboratories. A high DNA integrity number led to excellent depth and reliable NGS results. By conducting this pilot study using patient samples, we were able to obtain a glimpse of the current status of cancer genome testing at participating laboratories. To enhance domestic cancer genome testing, it is important to conduct local PT and to involve the parties concerned as organizers and participants.
Funder
Japan Society for the Promotion of Science
Pfizer
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献